Compare Royal Bank of Canada (RY) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs Smith & Nephew plc — how do they compare? Royal Bank of Canada trades at $191.77 (market cap $262.99B), while Smith & Nephew plc trades at $27.17 (market cap $11.10B). The key difference: Royal Bank of Canada is far larger — about 23.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Royal Bank of Canada for 47 Days and Smith & Nephew plc for 120 Days on average.
| RY | SNN | |
|---|---|---|
Market Cap | $262.99B | $11.10B |
Volume | 1,016,377 | 1,051,703 |
Sector | Financials | Health |
52-Week High | $217.87 | $37.17 |
52-Week Low | $143.64 | $26.42 |
Typical Hold Time | 47 Days | 120 Days |
Enterprise Value | $730.11B | $14.13B |
Dividend Yield | 2.66% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $191.22, down 2.61% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $3.07 versus $2.89 expected, and robust profitability with a 32.01% net income margin. Revenue growth accelerated to $66.53B in 2025, and the company maintains a solid dividend, with recent payouts of $1.76 per share. Analyst sentiment is mixed, with a Buy consensus of 43% but technical indicators pointing to near-term pressure.
RY presents a value opportunity with a reasonable P/E of 17.2 and strong ROE of 17.2%, supported by earnings momentum and strategic initiatives like global transaction banking integration. Risks include stretched valuations relative to peers, a high EV/EBITDA of 23.52, and macroeconomic sensitivity. The stock's current price near support at $189 suggests potential stability, but investors should weigh fundamental strength against technical bearishness and sector headwinds.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
